Kymera Therapeutics (NASDAQ:KYMR) Sets New 52-Week High at $49.06

Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $49.06 and last traded at $48.52, with a volume of 410718 shares traded. The stock had previously closed at $46.50.

Analyst Upgrades and Downgrades

KYMR has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $46.00 price objective on shares of Kymera Therapeutics in a research note on Monday, June 17th. Oppenheimer restated an “outperform” rating and set a $52.00 price objective on shares of Kymera Therapeutics in a research note on Wednesday, July 10th. Morgan Stanley upped their price objective on Kymera Therapeutics from $34.00 to $45.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 14th. Wells Fargo & Company upped their price objective on Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a research note on Monday, August 12th. Finally, B. Riley increased their price target on Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 9th. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $45.90.

Kymera Therapeutics Price Performance

The firm has a market cap of $2.93 billion, a price-to-earnings ratio of -19.04 and a beta of 2.22. The company has a fifty day moving average price of $39.37 and a two-hundred day moving average price of $37.93.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.10. The business had revenue of $25.60 million during the quarter, compared to analyst estimates of $12.55 million. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. The company’s revenue was up 55.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.67) earnings per share. On average, research analysts expect that Kymera Therapeutics, Inc. will post -2.86 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Joanna Horobin sold 8,500 shares of the company’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $32.99, for a total transaction of $280,415.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Bruce Booth sold 16,740 shares of the stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $35.45, for a total value of $593,433.00. Following the completion of the sale, the director now directly owns 803,792 shares of the company’s stock, valued at approximately $28,494,426.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Joanna Horobin sold 8,500 shares of the stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $32.99, for a total value of $280,415.00. The disclosure for this sale can be found here. Insiders sold a total of 502,345 shares of company stock valued at $19,279,932 over the last three months. Insiders own 15.82% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Several hedge funds have recently bought and sold shares of KYMR. Mirae Asset Global Investments Co. Ltd. increased its position in Kymera Therapeutics by 2.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,940 shares of the company’s stock worth $584,000 after purchasing an additional 524 shares during the last quarter. Russell Investments Group Ltd. increased its position in Kymera Therapeutics by 57.9% in the 4th quarter. Russell Investments Group Ltd. now owns 49,111 shares of the company’s stock worth $1,250,000 after purchasing an additional 17,999 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in Kymera Therapeutics in the 4th quarter worth about $246,000. Charles Schwab Investment Management Inc. increased its position in Kymera Therapeutics by 1.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 306,692 shares of the company’s stock worth $7,808,000 after purchasing an additional 4,951 shares during the last quarter. Finally, Norges Bank acquired a new position in Kymera Therapeutics in the 4th quarter worth about $12,834,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.